Back to companies

Idorsia Pharmaceutical Ltd: Premium Databases

Idorsia Pharmaceutical Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

A sample of Idorsia Pharmaceutical Regulatory Milestones data

Drug Name Generic Name Brand Name Company Name Expiry Geography Constraining Patent Number Constraining Patent Expiry Drug Expiry (Estimated) Highest Development Stage
Showing 3 of 9 results.
Deserunt mollit sunt Lorem Lorem Lorem Pfizer Inc Lorem WXYZ Lorem Pending Lorem
ACT-10041239 - - Idorsia Pharmaceutical Ltd United States US10752620 Jul-2037 - -
ACT-10041239 - - Idorsia Pharmaceutical Ltd EU EP3490986 Jul-2037 - -
ACT-539313 - - Idorsia Pharmaceutical Ltd Japan JP5718535 Nov-2032 - -

A sample of Idorsia Pharmaceutical Ltd Review Designation data

Drug Name Generic Name Company Name Indication Geography Designation Type Designation Status Designation Date
Showing 3 of 9 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore Lorem Pfizer Inc Lorem Lorem Lorem Lorem 10 Dec 2021
NBI-827104 - Neurocrine Biosciences Inc Epileptic Encephalopathy United States Orphan Drug Designation Designated 08 Apr 2021
NBI-827104 - Idorsia Pharmaceutical Ltd Epileptic Encephalopathy United States Rare Pediatric Disease Designation Designated -
daridorexant hydrochloride daridorexant hydrochloride Idorsia Pharmaceutical Ltd Insomnia United States Standard Review Designated/Approved 10 Mar 2021
Regulatory Milestones

Feature

Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

Benefit

Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.

The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.

US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).

Value

Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .

Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.

Premium databases is part of our industry range of products

Gain a 360-degree view of Idorsia Pharmaceutical Ltd and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Start of HubSpot Embed Code End of HubSpot Embed Code